Chelsea Therapeutics reports 'Significant Efficacy' of CH-4051 in reduction of Collagen-Induced Arthritis in animal model

Briefing.com

Posted: 2008-03-25 07:48:12

Co. announces positive results from a preclinical study to investigate the use of CH-4051, the second compound from its portfolio of metabolically inert antifolates, to treat rheumatoid arthritis. This 17-day study was designed to test the efficacy of CH-4051 in a rat collagen-induced arthritis (CIA) model. The results reveal a remarkable level of efficacy in delaying the onset of the disease, significantly decreasing the severity and, at certain doses, completely blocking all development of rheumatoid arthritis. The most significant finding from this study was that once daily dosing of 10mg/kg of CH-4051 administered from day 0 completely prevented the onset of arthritis.